An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)

High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

Part 1: Number of Participants Experiencing an Adverse Event (AE), Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs), Part 1: Number of Participants who Discontinued Study Treatment Due to an AE, Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0, Part 2: Number of Participants Experiencing an Adverse Event (AE), Part 2: Number of Participants who Discontinued Study Treatment Due to an AE

Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0 ypN0, Part 2: Event-Free Survival (EFS), Part 2: Overall Survival (OS), Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS), Part 2: Residual Cancer Burden (RCB)

No related papers found yet.

Spain